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Abstract 
Problem. Ordering genomic testing for patients with pancreatic cancer can discover 
germline or somatic mutations that may allow for targeted therapy. There are some 
difficulties in obtaining genomic tests, such as which test to order, and optimal timing of 
ordering. In addition, interpreting results and maintaining easy access to the report in the 
electronic medical record can be difficult. Delays in ordering genomic testing can delay 
the discovery of an actionable mutation for treatment.  
Methods. A descriptive comparison project was developed comparing rates and timing of 
ordering of genomic testing for patients with pancreatic cancer who established care with 
a medical oncology practice between December 2019 and April 2020, and December 
2020 and April 2021. Between the two data collection periods, medical oncologists began 
ordering genomic testing of pancreatic cancer patients upon initial consultation. 
Previously, there was no standard process of ordering genomic testing. The sample 
included adult patients at a Midwestern community medical oncology practice.  
Results. The mean number of days from tissue diagnosis of pancreatic cancer to ordering 
of genomic testing decreased from 56.7 days in the first group (n=6) to 13 days in the 
second group (n=5). No actionable mutations were found in either group.  
Implications for Practice. Early genomic testing of pancreatic cancer can lead to earlier 
discovery of genetic mutations and opportunities for matched targeted therapy, which 
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Standardizing Genomic Testing of Pancreatic Cancer in a Community Oncology 
Practice 
Pancreatic cancer is a malignancy with a poor prognosis. As this disease generally 
does not exhibit early symptoms, it may not be discovered until it is at an advanced stage, 
and it is currently the fourth leading cause of cancer death in the United States (Siegel, 
Miller, & Jemal, 2020). Over the next decade, pancreatic cancer is expected to rise to the 
second leading cause of cancer death (Pishvaian et al., 2020). For those diagnosed with 
locally advanced disease, median survival is 15-months, and for those diagnosed with 
metastatic disease, median survival decreases to only three- to six-months (Dai et al., 
2019). The foundation of treatment is chemotherapy, typically in regimens of combined 
medications, which can be given as neoadjuvant treatment before surgery, adjuvant 
treatment after surgery, or alone when given for metastatic disease (Krepline et al., 2020). 
In recent years, the development of precision medicine has attempted to change the 
treatment landscape for many malignancies, including pancreatic cancer.   
 Precision medicine uses an individual patient’s genetic information to find 
targeted therapy to match genetic alterations, both somatic and germline. Matched 
targeted therapy has the potential to provide successful treatment with lower toxicity to 
the patient, which has been demonstrated in studies for lung cancer and breast cancer 
(Singhi et al., 2019). Though a variety of mutations may be found using the standard tests 
of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), genetic 
testing is often done through molecular next generation sequencing (NGS) technology 
(Levit et al., 2019). Studies have shown that actionable somatic mutations exist in about 
25% of pancreatic cancers. Actionable mutations have an approved medication targeted 
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for that mutation specifically. Some of these mutations include mismatch repair (MMR) 
deficiency, ROS1, NTRK1, NTRK2, NTRK3, and BRAF. In addition, pancreatic cancer 
patients with germline BRCA1 and BRCA2 mutations have recently had targeted therapy 
approved (Pishvaian, 2020). These targeted therapies can potentially improve the 
outcome for those with pancreatic cancer significantly. However, obtaining NGS 
molecular profiles can be difficult, with multiple barriers to obtaining the tests and 
difficulty interpreting and maintaining the tests once they are completed.   
 The initial barrier to obtaining NGS begins with which test to order. Many 
companies provide NGS molecular profiling, with panels ranging from a targeted group 
of genes to whole genome sequencing. The type of tissue needed also varies and can be 
performed on tissue directly from the tumor or from circulating tumor cells found in the 
blood (Malone, Oliva, Sabatini, Stockley, & Siu, 2020). Once testing has been ordered 
and resulted, the report itself can be complex and difficult to interpret. In addition to 
reporting mutations that may have an associated targeted therapy, variations of unknown 
significance are often found. Clinicians may not have the understanding or time to fully 
interpret the findings of these complicated reports. Many of these tests are done by 
commercial laboratories outside of health systems, and the reports can be difficult to store 
in the electronic health record (EHR) for easy retrieval in the future (Levit et al., 2019). 
Optimal timing of when to order molecular profiling is also not well documented, as they 
are generally not done unless cancer is metastatic. However, studies are in progress to 
determine if targeted therapy may have a role in the adjuvant setting following 
neoadjuvant chemotherapy and surgical resection in pancreatic cancer (Krepline et al., 
2020).           
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 In a Midwestern suburban community oncology clinic, there had previously been 
no consistent process for molecular profiling of pancreatic cancer patients. However, 
over the last 12 months, somatic and germline testing for pancreatic cancer was being 
ordered upon establishing care with the medical oncologist. Previously, although 
genomic testing was being ordered for pancreatic cancer patients, there was no standard 
practice of when to order them. The aim of this project is to determine the impact of early 
molecular profiling of pancreatic cancer patients as compared to previous way of 
ordering. The goal is to have molecular profiling performed within two-months of tissue 
diagnosis in 90% of adult patients diagnosed with pancreatic cancer of any stage. The 
primary outcome measure of interest is molecular profiling rates with secondary outcome 
measures including the time from diagnosis and the number of actionable mutations 
found. The question of study is in adult patients in a Midwestern community medical 
oncology practice, what is the impact of early molecular profiling? The Iowa Model of 
Evidence-Based Practice was the framework used to guide this project. 
                                                   Literature Review 
The literature search for this project began with three search engines: MEDLINE, 
PubMed, and Cumulative Index of Nursing and Allied Health Literature (CINAHL). The 
key search terms used were “pancreatic cancer” AND “molecular profiling”, “pancreatic 
cancer patient” AND “molecular profiling”, and “pancreatic cancer” AND “precision 
medicine”.  The total number of all articles found with the above search terms was 
109,784. The search was further refined with inclusion and exclusion criteria. Inclusion 
criteria included adult studies, articles published since 2015, and those that were peer-
reviewed. Pediatric patients were excluded from the search. After applying inclusion and 
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exclusion criteria, the search generated 69,155 articles, with most of the articles returned 
from the PubMed search engine. Ultimately, 10 articles were selected for this literature 
review to include the various aspects concerning genomic testing. The evidence table for 
these articles can be found in Appendix A. The articles were selected to obtain evidence 
supporting the use of molecular profiling for pancreatic cancer, and to find evidence of 
the current practice of molecular profiling across the globe.     
 The use of NGS was discussed in most of the chosen articles. NGS may be 
performed by in-house or commercial laboratories, and though no study reported benefit 
of one test over another, multiple options exist. Kim et al. (2017) reported using 
CancerSCAN, a custom-made genomic panel for their medical center, which can evaluate 
up to 381 cancer-related genes. Other studies using an institutional laboratory were from 
Sholl et al. (2016), who performed molecular profiling with their tests, OncoMap and 
OncoPanel, and the study from Mitri et al. (2018) who utilized GeneTrails, a 124 gene 
test. The commercial laboratories Caris Life Sciences and Foundation Medicine were 
used in multiple studies (Krepline et al., 2020; Pishvaian et al., 2020; Wheler et al, 2016). 
Caris testing included two panels: a 53 gene test, as well as Caris Molecular Intelligence, 
a 472 gene test. Foundation Medicine provided a 472 gene panel test, Foundation One. 
Sunami et al. (2019) used an NGS panel of 114 genes with the National Cancer Center 
Oncopanel Test. The Know Your Tumor trial utilized a variety of laboratories, with the 
majority (97%) from the commercial laboratories of Foundation Medicine or Caris Life 
Sciences, and the remaining 3% from either in-house pathology or other commercial 
companies (Pishvaian et al., 2020).        
 The acquisition of specimens for NGS testing varied in the studies reviewed. 
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Mitri et al. (2018) performed new biopsies specifically for genomic testing, though many 
studies performed NGS on previously obtained tissue. Kaderbhai et al. (2016) used 
previously biopsied samples from 2012-2014. Krepline et al. (2019) used specimens from 
biopsies of pancreatic cancer patients from those who completed neoadjuvant 
chemotherapy and surgery between 2013 and 2018. An international cohort of archived 
pancreatic cancer specimens was used to test NGS in a study by Singhi et al. (2019). 
Archived tissue was also used by Sunami et al. (2019). Either fresh biopsy or archived 
tissue were utilized by Wheler et al. (2016) and Kim et al. (2017). A significant limitation 
to all the above studies was that NGS was performed on tissue specimens only, and none 
included the use of blood-based tests.      
 The number of patients with mutations found using NGS was another theme 
reported throughout many of the articles. However, many articles discussed the use of 
NGS in a variety of solid tumor malignancies, not just pancreatic cancer. Many studies 
found most patients tested had at least one somatic genetic mutation, as high as 93% of 
participants in one study (Kaderbhai et al.,2016; Mitri et al., 2018; Sunami et al., 2019; 
Tsimberidou et al., 2017; Wheler et al., 2016). However, the rate of actionable mutations 
was generally much smaller than the number of total mutations found. The IMPACT trial 
found that 82.1% of patients had at least one genetic mutation, but only 54% had an 
actionable mutation (Tsimberidou et al., 2017). A study from Kim et al. (2017) of solid 
tumors found that only 44.7% of 418 patients had an actionable mutation. Despite the 
presence of actionable mutations, targeted therapy is not always available, as 
demonstrated by Sholl et al. (2016). They found 73% of their patients had an actionable 
mutation, but only 19% with a currently approved medication. Two studies reported data 
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specifically for pancreatic cancer and had a lower incidence of actionable mutations as 
compared to solid tumors in general. Pishvaian et al. (2020) found that 26% of 1,082 
samples of those with pancreatic cancer had an actionable mutation. Singhi et al. (2019) 
reported that 17% of 3,594 pancreatic ductal carcinoma specimens had a mutation with a 
currently available targeted medication and found that 88% of all specimens had a KRAS 
mutation, of which there is no current approved targeted therapy. This certainly 
represents an area of future research and drug development.     
 Though many NGS panels are ordered, it was discovered through the various 
studies that there were often patients who were unable to have successful NGS profiling 
completed. The SHIVA trial had test rate success of only 69.2%. The reasons for not 
having complete profiling were that many biopsies did not contain tumor cells, had 
insufficient cellularity, insufficient DNA, or experienced run failures (Le Tourneau et al., 
2015). Low DNA yield and/or low tissue cellularity was also found to be an issue for 
Sunami et al. (2019), Sholl et al. (2016), and Kim et al. (2017).     
 Molecular tumor boards were utilized in two of the studies reviewed. A molecular 
tumor board is a meeting attended by medical oncologists, advanced practice providers, 
pathologists, molecular biologists, and geneticists who review NGS reports for individual 
patients and make suggestions for therapy. Suggested therapies included clinical trial 
enrollment, approved targeted therapy, or targeted therapy in an off-label manor in the 
paper by Kaderbhai et al. (2016). Sunami et al. (2019) used a molecular tumor board 
which met twice a month to review cases and make treatment suggestions. This panel 
then provided their recommendations to the treating physician for decision making. 
 As previously stated, matched targeted therapy has the potential to provide 
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successful treatment with lower toxicity to the patient, with multiple studies reporting 
improvement in stable disease, increased time to treatment failure, and improved overall 
survival with matched targeted therapy (Tsimberidou, 2017; Wheler et al., 2016). 
Interestingly, the SHIVA trial, a phase II trial evaluating targeted molecular therapy 
versus physician choice in patients with metastatic solid tumor malignancies, found that 
there was no statistical significance in progression free survival in patients on targeted 
therapy. The one exception was those with RAF/MEK mutations, as they had slight 
improvement in progression-free survival. It was suggested that the negative result was 
due to certain medications given for genetic mutations which were later found to be 
ineffective (Le Tourneau et al., 2015). Specifically, regarding pancreatic cancer, the 
Know Your Tumor trial found that patients with matched therapy had significantly longer 
overall survival compared to those who did not receive matched therapy (2.58 years 
versus 1.51 years). Progression free survival was also significantly longer in matched 
versus unmatched therapy (10.93 months versus 4.53 months) (Pishvaian et al., 2020).  
 The Iowa Model was chosen for the evidence-based practice framework for this 
project. This model identifies the clinical problem that clinicians find important, which is 
called a trigger. The trigger in this project was the complexity of ordering NGS molecular 
profiling in current medical oncology practice. This model uses frequent feedback loops 
to continually evaluate the effectiveness of the intervention and uses a team approach in 
developing practice change (Melnyk & Fineout-Overholt, 2019). This model is valuable 
as the project required collaboration with multiple individuals including physicians, nurse 
practitioners, nurses, patients, and NGS laboratories to ensure patients with pancreatic 
cancer receive appropriate testing in a timely manner to provide the best potential 
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outcome.          
 In summary, pancreatic cancer is a malignancy with poor long-term survival, with 
less than nine percent 5-year survival rate (Singhi et al., 2019). The use of NGS testing in 
solid tumor malignancies to uncover targetable genetic mutations has increased in recent 
years. For those with pancreatic cancer, treatment with matched targeted therapy can 
improve survival outcomes, and studies have shown that actionable mutations exist in 
about 25% of pancreatic cancers. (Pishvaian et al., 2020). However, the process of 
obtaining NGS testing can be cumbersome, and is not always successful. While research 
is promising regarding the benefits of NGS, additional research is needed to evaluate 
successful genomic sequencing using blood-based specimens versus tissue-based 
samples, as this may influence the success rate of NGS sample testing. The results of 
NGS may also continue to lead researchers to the development of new, targeted 
medications. Developing this practice protocol for NGS testing may lead to finding 
actionable mutations to improve outcomes for pancreatic cancer patients in the Midwest. 
             Method 
Design            
 The design of this project is a descriptive comparison, comparing the rates and 
timing of NGS testing of pancreatic cancer patients establishing care with a medical 
oncology practice between December 2019 and April 2020 to pancreatic cancer patients 
establishing care between December 2020 and April 2021. Retrospective chart review 
was utilized.   
Setting           
 A Midwestern suburban community oncology clinic was the setting for this 
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project. The practice employs two full-time medical oncologists as well as two full-time 
nurse practitioners as part of a large multi-state health system. Over the previous three 
years this practice has averaged 785 new patients annually, with an average of 32 new 
adult pancreatic cancer patients annually.                          
Sample 
 A purposeful sample was taken to include all adult pancreatic cancer patients of 
any stage. Pediatric patients were excluded.        
                                          Approval Processes    
 Approval of this project was required and granted from the University of 
Missouri- St. Louis IRB as well as the health system IRB. Approval from the practice site 
was also granted.   
Data Collection/Analysis         
 Data that was collected included age, gender, stage of pancreatic cancer, date of 
tissue diagnosis, date of ordering of NGS testing, the presence of any actionable 
mutation, and the availability of matched targeted therapy.  The data collection tool is 
found in Appendix B. Data was collected on newly established pancreatic cancer patients 
from December 2019 to April 2020, and again from December 2020 to April 2021 
through retrospective chart review. An independent sample t-test was used to compare 
the differences in NGS testing between the previous way of ordering and after NGS 
testing was ordered on the first visit. Data was deidentified by using numbers in place of 
patient name. No date of birth or other patient identification was used.  
Procedures           
 Using the data collection tool, retrospective chart review and data collection was 
STANDARDIZING GENOMIC TESTING                                                                     12 
 
completed on subjects diagnosed with any stage of pancreatic cancer from December 
2019 to April 2020. Subjects were identified through a review of providers’ schedules in 
the given time frame in the Epic electronic health record. This process was repeated in 
May 2021, when retrospective chart review was done on subjects with pancreatic cancer 
establishing care with medical oncology between December 2020 to April 2021. Data 
was analyzed following the second data collection period.    
Results 
 Upon completion of data collection, a total of six subjects (n=6) were diagnosed 
with pancreatic cancer in the first group between December 2019 and April 2020. Four of 
the subjects were female (67%), and two of the subjects were male (33%). The age of the 
subjects ranged from 55-years-old to 85-years-old, with a mean average age of 72 years. 
Three subjects (50%) were diagnosed with stage II pancreatic cancer, and three subjects 
(50%) were diagnosed with stage IV disease. Regarding days from tissue diagnosis to 
ordering of genomic testing there was a range of nine days to 133 days, with a mean of 
56.7 days. No actionable mutations were found in this group, and thus no matched 
targeted therapy was available.  
Five subjects (n=5) were diagnosed with pancreatic cancer in the second group 
between December 2020 and April 2021. Three of the subjects were male (60%) and two 
subjects (40%) were female. The age of the subjects ranged from 60-years-old to 85-
years-old with a mean age of 70.6 years. One subject (20%) was diagnosed with stage II 
disease, three subjects (60%) were diagnosed with stage III disease, and one subject 
(20%) was diagnosed with stage IV disease. The range of days from tissue diagnosis to 
ordering of genomic testing in the second group had a range of six days to 17 days, with a 
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mean of 13 days. No actionable mutations were found in this group, and therefore no 
matched targeted therapy was available.   
Analysis of the data using an independent samples t-test for days from diagnosis 
to ordering of genetic testing between the groups did not demonstrate statistical 
significance (t(9) = 1.77, p = 0.111). There was also no statistical significance found 
between the age of the subjects in either group (t(9) = 0.20, p = 0.846). Using Chi-square 
analysis for gender  (χ2 = 0.782, df = 1, p = 0.376) and cancer stage (χ2 = 4.95, df = 2, p = 
0.084), no statistical significance was found between the two groups (Tables 2 and 3).  
Discussion 
 The purpose of this project was to determine the impact of early molecular 
profiling of pancreatic cancer patients, with a goal of 90% having molecular profiling 
ordered within two-months of tissue diagnosis. This goal was met with the second group 
having molecular profiling ordered less than one month from tissue diagnosis. Although 
this was not statistically significant as compared to the first group, there is definite 
clinical significance, as the mean days of testing was 56.7 days in the first group and only 
13 days in the second group. Decreased days to genomic testing could potentially 
uncover an actionable mutation with matched targeted therapy quickly, though this was 
not demonstrated in this sample.  
 No actionable mutations were found in any of the subjects of either the first or 
second group. These findings from this sample were not consistent with the national 
average of approximately 25% of pancreatic cancer patients with an actionable mutation 
(Pishvaian, 2020).  
Limitations 
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 There were several limitations to this project, with the most significant being a 
small sample size. A larger sample size may have improved statistical significance as 
well as potentially finding the presence of actionable mutations and matched targeted 
therapy.  
 Another limitation was having an open data collection period of four months. As 
cancer diagnosis is unpredictable, there may potentially have been a number of subjects 
that were unable to be included due to this limitation. The location of this project 
averages 32 new pancreatic cancer patients annually, however, they may not be evenly 
distributed throughout the 12 months of the year. Having a longer time for data collection 
would possibly capture more subjects appropriate for inclusion.      
 A barrier found during this project was the data collection method. Due to 
administrative barriers of searching for patients in the EMR by cancer diagnosis, 
considerable time was spent in reviewing physician and nurse practitioner clinic 
schedules to search for patients with a new diagnosis of pancreatic cancer. This method 
of searching can lead to the potential of missed subjects who may have not been easily 
discovered in the search.  
Conclusion 
 Studies have demonstrated the potential for improvement of patient outcomes 
with the adoption of precision medicine and matched targeted therapy in pancreatic 
cancer. This project demonstrated that though there was not statistical significance in this 
sample, it did demonstrate clinical significance. As early identification of genetic 
mutations may lead to better treatment outcomes for patients, this descriptive comparison 
project demonstrated a clinically significant decrease in the mean number of days of 
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genomic testing of pancreatic cancer patients.       
 Adopting a model of ordering of both germline and somatic genetic testing for 
pancreatic cancer patients upon initial consultation with the medical oncology team has 
shown that time to ordering genetic testing decreased from a mean of 56.7 days to a mean 
of 13 days. The benefits of ordering genomic testing upon consultation with pancreatic 
cancer patients can be easily disseminated to other medical oncology providers in the 
health system. This could result in genetic mutations being found more quickly, allowing 
for matched targeted therapy when available. These findings can also be relevant to the 
nursing and other support staff in the medical oncology practice, as often these groups are 
involved in the logistics of ordering genomic testing.     
 The implications of NGS testing for pancreatic cancer patients upon consultation 
with medical oncology could improve the rates of these tests ever being ordered, 
especially in community oncology practices, as studies have demonstrated that 
community practices order less genomic testing for their patients as compared to 
academic centers. Improving the rates of genetic testing has the opportunity to improve 
patient outcomes for not only pancreatic cancer patients but all cancer patients, especially 
in rural areas as well as other underserved areas generally served by community oncology 
practices (Ball et al., 2020).    
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pancreatic cancer.  
This trial didn’t show 
improvement in 

























group (surprising).  
 
Strengths: If matched 
treatment was 
available, it could be 
given off label. There 
was an adequate # 
enrolled in the trial.  
 
Recommendations: 
Repeat study with 
single tumor types 
specifically. Could 
look more into off-
label use of 
medications for 
specific mutations by 
malignancy. 
Mitri, Z., Parmar, 
S., Johnson, B., 

































































platform, ability to 
biopsy as needed.  
 
Limitations: 
Small sample size, 
limitation of cancers 
tested, one location of 
study, exclusion of two 




Use these results to 
continue to develop 
treatments based on 
presence of actionable 
mutations, develop 
molecular tumor board 
to assist in managing 
these patients 
Pishvaian, M., 













analysis of the 
Know Your Tumor 
registry trial. Lancet 
Oncology, 21 (4), 
508-518. 
 
To see if patients 
with matched 
molecular therapy 
had longer median 





















































sample size, sample 
came from all over the 





therapy was combined 
with chemotherapy, 
patients were enrolled 
at various points in 
their treatment and 




This will serve as 
foundation for future 
clinical trials looking 






















Cerami, E., Dubuc, 





profiling on an 
unselected cancer 
population. JCI 







new predictors of 
















































analysis as it is not a 
clinical trial 
 
Strengths: They looked 





collected to see if 
whole genome 
sequencing vs targeted 
gene panels may be 
more cost effective 
and appropriate for 
certain malignancies 
Singhi, A., George, 
B., Greenbowe, J., 










might be targeted 
with existing drugs 
or used as 
biomarkers. 
Gastroenterology, 


















































number studied. Data 
shows that this is a 
feasible program  
 
Recommendations: 
Use results to look 
further into IPMN 
transformation and 




Ichikawa, H., Kubo, 





and utility of a 
panel testing for 
114 cancer-
associated genes in 








utility of NGS 





































Limitations: did not 
look at response rate of 
actionable 
mutations/matched 




Use of this data to 
assist in the 
development of 
targeted drugs for 
various mutations 
found in solid tumor 
malignancies 
Tsimberidou, A., 











































number of study 
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A…Kurzrock, R. 



























1179 ad one 
or more 
alteration, 







































Use these results to 
help develop a testing 
program outside of 
academic center. 
Could also further test 
by individual 
malignancy 
Wheler, J., Janku, 
F., Naing, A., Li, 




therapy directed by 
comprehensive 
genomic profiling: a 
single center study. 
Cancer Research, 




response rate of 

































phase 1 drugs given, 
physicians could 
choose therapy, many 





Large sample size, 
multiple tumor types, 
was done as it would 
be done in a regular 
practice vs trial 
 
Recommendations: 
Can be used to develop 
program for matched 
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Appendix B 
Data Collection Tool
 
 
